Center for Health Equity Research and Promotion

Profile

Dr. Gellad's research focuses on optimizing the quality, safety, and value of prescribing and prescription drug use. He was the recipient of a career development award from the Department of Veterans Affairs and is now the principal investigator on grants from the VA, NIH, and private foundations for multiple studies of pharmaceutical policy and prescription use. With an R01 from the National Institute on Drug Abuse (NIDA), he currently leads a research team developing machine learning models predicting opioid related adverse events using healthcare and social services data. He has authored more than 230 research articles, editorials, and commentaries in leading medical and policy journals, and he is a regular commentator on pharmaceutical policy issues in major news outlets. He is a former member of the Food and Drug Administration (FDA) advisory committee on nonprescription drugs and FDA Drug Safety Oversight Board. In 2019, he received the Presidential Early Career Award for Scientists and Engineers (PECASE), and he is an elected member of the American Society for Clinical Investigation.

Dr. Gellad is board certified in internal medicine and completed a residency and chief residency in internal medicine at Brigham and Women's Hospital and Harvard Medical School. He sees primary care patients in the VA Pittsburgh Healthcare System and attends on the inpatient general medical service.